Literature DB >> 11198154

Role of prostanoids and nitric oxide inhibition in rats with experimental hepatic fibrosis.

M Criado1, O Flores, M J Vázquez, A Esteller.   

Abstract

Nitric oxide (NO) and prostaglandins have been proposed as vasodilator substances involved in peripheral vasodilatation characteristic of the liver cirrhosis. A link between NO and prostanoids has been suggested. The present study investigated the effect of simultaneous blockade of both, NO synthase (NOS) and cyclooxigenase (COX) in sham-operated (SO), or rats with bile-duct ligation (BDL) in the development of liver fibrosis. Animals were distributed in two groups SO (n=15) or BDL (n=15). Treatments (5 days) started three weeks after surgical procedure. Both, SO and BDL animals were treated with indomethacin (INDO) (5 mg/kg/day) alone, with NG-nitro-L-arginine-methyl-ester (NAME) (4 mg/kg/day) alone or with INDO and NAME combination at the same doses. At the end of follow-up body weight, packed cell volume, mean arterial blood pressure (MAP) and heart rate were measured. Liver tissue was processed for histological studies. In this study, BDL animals showed a decreased MAP. Treatment with L-NAME in BDL rats increased MAP. The chronic COX inhibition alone did not play an important role in the haemodynamic changes. The BDL produced a loss of hepatic structure, with ductular metaplasia that occupied the greater part of the hepatic parenchyma. Also, an important degree of fibrosis was observed. Both NO and PG synthesis inhibitors, alone or in combination, induced enhancing collagen fiber deposition in the hepatic parenchyma. These findings support the notion that the interaction between the NOS and COX pathways should be relevant in hepatic cirrhosis in which both NOS and COX are induced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11198154     DOI: 10.1007/bf03179785

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  16 in total

1.  Elevated glomerular and blood mononuclear lymphocyte nitric oxide production in rats with chronic bile duct ligation: role of inducible nitric oxide synthase activation.

Authors:  M Criado; O Flores; M C Ortíz; F Hidalgo; A M Rodríguez-López; N Eleno; N M Atucha; A Sánchez-Rodríguez; M Arévalo; J Garcia-Estañ; J M López-Novoa
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

2.  Interaction between prostanoids and nitric oxide in the control of tubular function in rats with chronic bile duct ligation.

Authors:  M Criado; O Flores; F Hidalgo; J M López-Novoa; A Sánchez-Rodríguez
Journal:  Can J Physiol Pharmacol       Date:  1999-02       Impact factor: 2.273

3.  Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide.

Authors:  F J Salazar; J M Pinilla; F López; J C Romero; T Quesada
Journal:  Hypertension       Date:  1992-07       Impact factor: 10.190

4.  Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation.

Authors:  P Mayoral; M Criado; F Hidalgo; O Flores; M A Arévalo; N Eleno; A Sánchez-Rodríguez; J M López-Novoa; A Esteller
Journal:  Clin Sci (Lond)       Date:  1999-03       Impact factor: 6.124

5.  Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis.

Authors:  A Fabbri; D Magalotti; M Brizi; G Bianchi; M Zoli; G Marchesini
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

6.  Origin and involution of hyperplastic bile ductules following total biliary obstruction.

Authors:  J A Gall; P S Bhathal
Journal:  Liver       Date:  1990-04

7.  Hepatic and gastric cytoprotective effects of long-term prostaglandin E1 administration in cirrhotic rats.

Authors:  P L Beck; G W McKnight; J K Kelly; J L Wallace; S S Lee
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

8.  Increased nitric oxide synthesis and inducible nitric oxide synthase expression in patients with alcoholic and non-alcoholic liver cirrhosis.

Authors:  A Sánchez-Rodríguez; M Criado; A M Rodríguez-López; A Esteller; A Martín de Arriba; J M López-Novoa
Journal:  Clin Sci (Lond)       Date:  1998-06       Impact factor: 6.124

9.  Long-term administration of PGE1 increases liver fibrosis and collateral blood flow in bile-duct-ligated rats.

Authors:  J Fort; C Pilette; F Oberti; N Veal; Y Gallois; O Douay; P Calès
Journal:  J Hepatol       Date:  1999-01       Impact factor: 25.083

10.  Modulation by nitric oxide of prostaglandin biosynthesis in the rat.

Authors:  L Sautebin; A Ialenti; A Ianaro; M Di Rosa
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more
  3 in total

1.  The role of iNOS in cholesterol-induced liver fibrosis.

Authors:  Sarit Anavi; Michal Eisenberg-Bord; Michal Hahn-Obercyger; Olga Genin; Mark Pines; Oren Tirosh
Journal:  Lab Invest       Date:  2015-06-22       Impact factor: 5.662

2.  iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis.

Authors:  Alexandre T J Maria; Pauline Rozier; Guillaume Fonteneau; Thibault Sutra; Marie Maumus; Karine Toupet; Jean-Paul Cristol; Christian Jorgensen; Philippe Guilpain; Danièle Noël
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

3.  Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system.

Authors:  Sherzad K Rashid; Noureddine Idris-Khodja; Noureddine Idris Khodja; Cyril Auger; Mahmoud Alhosin; Nelly Boehm; Monique Oswald-Mammosser; Valérie B Schini-Kerth
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.